$EPRX

$6.85 -$0.02 (0.29%) Close

$EPRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 40.0M shares outstanding

Who owns EPRX?

By type of holder

Institutions 62.1% Everyone else 37.9%

No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".

Concentration Top 10 holders own 48.6%

Joseph S. Freedman 14.6% · Beutel, Goodman & Co Ltd. 9.1%

Institutional ownership

62.1%

+6.4 pts vs last qtr

Institutional holders

+12 vs last qtr

Net shares bought

+2.6M

by institutions in Q2 2026

New / sold out

18 / 6

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jupiter Topco LLC NEW +1.0M
PFM Health Sciences, LP +669.8K

Biggest sellers in Q2 2026

Squadron Capital Management LLC SOLD OUT −680.0K
Ally Bridge Group (NY) LLC −408.2K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Eupraxia Pharmaceuticals Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2022–FY2025

+107.2%

+27.48% a year

Each share's claim on the business

−51.7%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $14.8M

over 4 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years12% Under 1 year88%

Quarterly turnover

18.4%

of institutional shares changed hands

Top 10 managers, median time held

3 quarters

Super Investors

Investment managers reporting EPRX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
BG Beutel, Goodman & Co Ltd.	3.6M	9.08%	−38.6K (−1.1%)	Q3 '25	0.2%
Shares held by quarter Peak holding4.1M (Q3'25) Change over 8 quarters+3.6M Share of the company9.080% Beutel, Goodman & Co Ltd.'s full portfolio →
AA Affinity Asset Advisors, LLC	1.7M	4.13%	+61.0K (+3.8%)	Q3 '25	0.5%
Shares held by quarter Peak holding1.7M (Q2'26) Change over 8 quarters+1.7M Share of the company4.130% Affinity Asset Advisors, LLC's full portfolio →

Beutel, Goodman & Co Ltd.

3.6M

% of company

9.08%

Change vs last qtr

−38.6K (−1.1%)

Held since

Q3 '25

Affinity Asset Advisors, LLC

1.7M

% of company

4.13%

Change vs last qtr

+61.0K (+3.8%)

Held since

Q3 '25

28 more super investors behind a free account

See every manager holding Eupraxia Pharmaceuticals Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting EPRX on Form N-PORT; together they hold 0.1% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FN Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust	$257K	36.2K	0.09%	0.00%	May 31, 2026
BA Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds	$1.98K	300	0.00%	0.00%	June 30, 2026

Fidelity Nasdaq Composite Index Fund

Fidelity Concord Street Trust

Position value

$257K

% of company

0.09%

% of the fund

0.00%

As of

May 31, 2026

Blackstone Alternative Multi-Strategy Fund

Blackstone Alternative Investment Funds

Position value

$1.98K

% of company

0.00%

% of the fund

0.00%

As of

June 30, 2026

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
JS Joseph S. Freedman 5%+ holder 13D · 9.0%	5.8M	14.62%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company14.620% Disclosed stake13D · 9.0% View the 13D/G filing →

Joseph S. Freedman

5%+ holder13D · 9.0%

5.8M

% of company

14.62%

Change vs last qtr

—

Held since

—

Comments